Ian M Leitch
Overview
Explore the profile of Ian M Leitch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wykoff C, Jackson T, Price C, Baldwin M, Leitch I, Slakter J
Ophthalmic Surg Lasers Imaging Retina
. 2025 Feb;
:1-10.
PMID: 39999360
Background And Objective: The purpose of this study was to evaluate the angiographic predictors of response to the anti-vascular endothelial growth factor-C/-D agent, sozinibercept. Patients And Methods: Prespecified and post...
2.
Boyer D, Steinle N, Pearlman J, Stone C, Crawford C, Gupta S, et al.
Transl Vis Sci Technol
. 2024 Dec;
13(12):32.
PMID: 39699889
Purpose: Sozinibercept inhibits vascular endothelial growth factors (VEGFs) C and D. This study evaluated outcomes following switching from anti-VEGF-A monotherapy to intravitreal injections of three dose levels of sozinibercept in...
3.
Leitch I, Gerometta M, Eichenbaum D, Finger R, Steinle N, Baldwin M
Ophthalmol Ther
. 2024 Jun;
13(7):1857-1875.
PMID: 38824253
The development of treatments targeting the vascular endothelial growth factor (VEGF) signaling pathways have traditionally been firstly investigated in oncology and then advanced into retinal disease indications. Members of the...
4.
Dugel P, Boyer D, Antoszyk A, Steinle N, Varenhorst M, Pearlman J, et al.
Ophthalmol Retina
. 2020 Jan;
4(3):250-263.
PMID: 31924544
Purpose: OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D. A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined with ranibizumab...
5.
Rosen P, Sweeney C, Park D, Beaupre D, Deng H, Leitch I, et al.
Clin Cancer Res
. 2010 Apr;
16(9):2677-87.
PMID: 20406832
Purpose: This phase Ib study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AMG 102, a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in combination with...
6.
Gordon M, Sweeney C, Mendelson D, Eckhardt S, Anderson A, Beaupre D, et al.
Clin Cancer Res
. 2010 Jan;
16(2):699-710.
PMID: 20068101
Purpose: The aims were to assess the safety, pharmacokinetics, maximum tolerated dose, and antitumor activity of AMG 102, a fully human hepatocyte growth factor/scatter factor (HGF/SF)-neutralizing monoclonal antibody, in patients...